Half-year report · HY
4820.TEDINET S100YVT8
Period2026-01-01 → 2026-06-30
Filed2026-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥10.4bn | 2026-01-01 → 2026-06-30 | Cons. | Net sales |
| Revenue | ¥23.7bn | 2025-01-01 → 2025-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥12.1bn | 2025-01-01 → 2025-06-30 | Cons. | Net sales |
| Operating income | ¥922m | 2026-01-01 → 2026-06-30 | Cons. | Operating income |
| Operating income | ¥2.1bn | 2025-01-01 → 2025-06-30 | Cons. | Operating income |
| Ordinary income | ¥1.3bn | 2026-01-01 → 2026-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥4.3bn | 2025-01-01 → 2025-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.4bn | 2025-01-01 → 2025-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.1bn | 2026-01-01 → 2026-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥2.3bn | 2025-01-01 → 2025-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥663m | 2026-01-01 → 2026-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.5bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.6bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥660m | 2026-01-01 → 2026-06-30 | Cons. | Profit loss |
| Net income | ¥1.6bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss |
| Total assets | ¥26.8bn | at 2026-06-30 | Cons. | Assets |
| Total assets | ¥27.5bn | at 2025-12-31 | Cons. | Assets |
| Total assets | ¥29.0bn | at 2025-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥6.8bn | at 2026-06-30 | Cons. | Liabilities |
| Total liabilities | ¥7.1bn | at 2025-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥20.0bn | at 2026-06-30 | Cons. | Net assets |
| Net assets / equity | ¥20.4bn | at 2025-12-31 | Cons. | Net assets |
| Net assets / equity | ¥20.5bn | at 2025-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥6.6bn | at 2026-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥7.8bn | at 2025-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥6.6bn | at 2026-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.8bn | at 2025-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.7bn | at 2025-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.9bn | at 2024-12-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.0bn | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.0bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.7bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥395m | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.2bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥568m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.9bn | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥3.8bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.2bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥9.58 | 2026-01-01 → 2026-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥35.44 | 2025-01-01 → 2025-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥23.18 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥9.55 | 2026-01-01 → 2026-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥35.32 | 2025-01-01 → 2025-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥23.1 | 2025-01-01 → 2025-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 74.3% | at 2026-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.9% | at 2025-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.4% | at 2025-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 42
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2026-01-01 → 2026-06-30 | −¥79m |
| Reconciling Itemsreconciling | revenue intersegment | 2026-01-01 → 2026-06-30 | −¥79m |
| Reconciling Itemsreconciling | segment profit | 2026-01-01 → 2026-06-30 | ¥19m |
| Care Welfare IT Systems Businessreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥411m |
| Care Welfare IT Systems Businessreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥411m |
| Care Welfare IT Systems Businessreportable segment | segment profit | 2026-01-01 → 2026-06-30 | −¥130m |
| Medicine Receipt Computer And Related Businessreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥1.2bn |
| Medicine Receipt Computer And Related Businessreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥1.2bn |
| Medicine Receipt Computer And Related Businessreportable segment | segment profit | 2026-01-01 → 2026-06-30 | −¥254m |
| Other Businessreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥538m |
| Other Businessreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥470m |
| Other Businessreportable segment | revenue intersegment | 2026-01-01 → 2026-06-30 | ¥68m |
| Other Businessreportable segment | segment profit | 2026-01-01 → 2026-06-30 | ¥11m |
| Pharmacy Receipt Computer And Related Businessreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥8.3bn |
| Pharmacy Receipt Computer And Related Businessreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥8.3bn |
| Pharmacy Receipt Computer And Related Businessreportable segment | revenue intersegment | 2026-01-01 → 2026-06-30 | ¥11m |
| Pharmacy Receipt Computer And Related Businessreportable segment | segment profit | 2026-01-01 → 2026-06-30 | ¥1.3bn |
| —segment total | revenue | 2026-01-01 → 2026-06-30 | ¥10.5bn |
| —segment total | revenue external | 2026-01-01 → 2026-06-30 | ¥10.4bn |
| —segment total | revenue intersegment | 2026-01-01 → 2026-06-30 | ¥79m |
| —segment total | segment profit | 2026-01-01 → 2026-06-30 | ¥902m |
| Reconciling Itemsreconciling | revenue | 2025-01-01 → 2025-06-30 | −¥68m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-01 → 2025-06-30 | −¥68m |
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-06-30 | ¥21m |
| Care Welfare IT Systems Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥262m |
| Care Welfare IT Systems Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥262m |
| Care Welfare IT Systems Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥169m |
| Medicine Receipt Computer And Related Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥1.5bn |
| Medicine Receipt Computer And Related Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥1.5bn |
| Medicine Receipt Computer And Related Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥80m |
| Other Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥571m |
| Other Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥512m |
| Other Businessreportable segment | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥59m |
| Other Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥23m |
| Pharmacy Receipt Computer And Related Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥9.9bn |
| Pharmacy Receipt Computer And Related Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥9.9bn |
| Pharmacy Receipt Computer And Related Businessreportable segment | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥9m |
| Pharmacy Receipt Computer And Related Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥2.1bn |
| —segment total | revenue | 2025-01-01 → 2025-06-30 | ¥12.2bn |
| —segment total | revenue external | 2025-01-01 → 2025-06-30 | ¥12.1bn |
| —segment total | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥68m |
| —segment total | segment profit | 2025-01-01 → 2025-06-30 | ¥2.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 521
| Item | Context | Value | Unit |
|---|---|---|---|
| Type1 semi annual consolidated balance sheet (text) | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated statement of income (text) | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated statement of comprehensive income (text) | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated statement of cash flows (text) | InterimDuration | Text · Plus | |
| Notes changes in scope of consolidation or equity method (text) | InterimDuration | Text · Plus | |
| Notes accounting treatments specific to semi annual financial statements type1 semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | InterimDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | InterimDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1InterimDuration | Text · Plus | |
| Notes regarding dividend (text) | InterimDuration | Text · Plus | |
| Notes business combinations semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes segment information etc type1 semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1InterimDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1InterimDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | InterimDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | InterimDuration | Text · Plus | |
| Notes revenue recognition semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes per share information semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes significant events after reporting period semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | InterimDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |